This application seeks renewed CCSG funding for the City of Hope Comprehensive Cancer Center (COHCCC). The COHCCC brings together 131 Members from 34 Departments in the City of Hope Medical Center and the Beckman Research Institute. The Center receives $24,212,096M (Totals) from NCI, $25,947,483M from other peer-reviewed sources, and $31,421,929M from non-peer-reviewed sources, for a total of $81,581,508M in overall funding. Through faculty recruitment, reorganization, and significant infrastructure development, the COHCCC has greatly enhanced its ability to accelerate clinical and translational cancer-focused research. Seventy-two new faculty have been recruited, including 48 clinical investigators and 24 basic and population research scientists. The Cancer Center has five Programs: Molecular Oncology (MONC), Developmental Cancer Therapeutics (DCT), Cancer Immunotherapeutics (CI), Hematologic Malignancies (HM), and Cancer Control and Population Sciences (CCPS). Center membership has been honed to sharpen cancer focus and an Associate Member category has been created for investigators whose potential for peer-reviewed, cancer-focused research is yet developing. This application requests support for ten Shared Resources: Analytical Cytometry, Analytical Pharmacology, Bioinformatics, Functional Genomics/Genomic Sequencing, Pathology, Small Animal Imaging, Drug Discovery and Structural Biology, Survey Research, Biostatistics, and Clinical Protocol and Data Management. The COHCCC is primed to make significant advances in the coming years. Our 72 new basic, population and clinical research recruits will continue to introduce new ideas, technologies, and areas of research focus while enhancing the creative and innovative environment of the Center. Significant infrastructure and other resources have been created to facilitate the translation of discoveries to the rapid development of new cancer treatments, diagnostic tests, and other interventions that would aid people with cancer, as well as individuals at risk for malignancy. Finally, the overall configuration of the institution and its administrative capabilities in terms of leadership, programmatic alignment, development, and authority that have been augmented so that the Cancer Center will be more responsive to its members and to harness their collective energies and creativity. This proposal documents that the COHCCC has built a solid structure for achieving its missions and is stronger and more sustainable than it has ever been.
; Organizational capabilities under the authority of the Cancer Center Director are key for appropriate leadership, evaluation and planning. This goal enhances the Cancer Center's dedication to developing innovative new disease-fighting strategies in the battle against cancer.
|Gu, Ying; Zhang, Jiawei; Ma, Xiaoxiao et al. (2017) Stabilization of the c-Myc Protein by CAMKII? Promotes T Cell Lymphoma. Cancer Cell 32:115-128.e7|
|Cao, Pengpeng; Mooney, Rachael; Tirughana, Revathiswari et al. (2017) Intraperitoneal Administration of Neural Stem Cell-Nanoparticle Conjugates Targets Chemotherapy to Ovarian Tumors. Bioconjug Chem 28:1767-1776|
|Mohanty, Suchismita; Mohanty, Atish; Sandoval, Natalie et al. (2017) Cyclin D1 depletion induces DNA damage in mantle cell lymphoma lines. Leuk Lymphoma 58:676-688|
|Wittenberg, Elaine; Ferrell, Betty; Koczywas, Marianna et al. (2017) Pilot Study of a Communication Coaching Telephone Intervention for Lung Cancer Caregivers. Cancer Nurs :|
|Yuan, Yuan; Vora, Nilesh; Sun, Can-Lan et al. (2017) Association of Pre-Chemotherapy Peripheral Blood Pro-Inflammatory and Coagulation Factors with Physical Function in Women with Breast Cancer. Oncologist 22:1189-1196|
|Deng, Ruishu; Hurtz, Christian; Song, Qingxiao et al. (2017) Extrafollicular CD4+ T-B interactions are sufficient for inducing autoimmune-like chronic graft-versus-host disease. Nat Commun 8:978|
|He, Zhiheng; Ma, Jian; Wang, Ruiqing et al. (2017) A two-amino-acid substitution in the transcription factor ROR?t disrupts its function in TH17 differentiation but not in thymocyte development. Nat Immunol 18:1128-1138|
|Kortylewski, Marcin; Moreira, Dayson (2017) Myeloid cells as a target for oligonucleotide therapeutics: turning obstacles into opportunities. Cancer Immunol Immunother 66:979-988|
|Somlo, George; Frankel, Paul H; Arun, Banu K et al. (2017) Efficacy of the PARP Inhibitor Veliparib with Carboplatin or as a Single Agent in Patients with Germline BRCA1- or BRCA2-Associated Metastatic Breast Cancer: California Cancer Consortium Trial NCT01149083. Clin Cancer Res 23:4066-4076|
|Slavin, Thomas P; Neuhausen, Susan L; Nehoray, Bita et al. (2017) The spectrum of genetic variants in hereditary pancreatic cancer includes Fanconi anemia genes. Fam Cancer :|
Showing the most recent 10 out of 1277 publications